Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BRUKINSA vs ACALABRUTINIB
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Zanubrutinib is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK). It forms a covalent bond with the cysteine residue at position 481 in the BTK active site, leading to sustained inhibition of BTK activity. This blocks B-cell receptor (BCR) signaling, thereby inhibiting the proliferation, migration, and survival of malignant B cells.
Acalabrutinib is a selective, irreversible inhibitor of Bruton tyrosine kinase. It forms a covalent bond with a cysteine residue in the active site, blocking B-cell receptor signaling and inhibiting malignant B-cell proliferation and survival.
Mantle cell lymphoma (MCL) in adult patients who have received at least one prior therapy,Waldenström's macroglobulinemia (WM) in adult patients,Relapsed or refractory marginal zone lymphoma (MZL) in adult patients who have received at least one prior anti-CD20-based regimen,Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in adult patients
Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy,Treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma
320 mg orally once daily or 160 mg orally twice daily.
100 mg orally every 12 hours.
4 hours (terminal), supports twice-daily dosing
Terminal elimination half-life is approximately 1 hour. Clinical context: short half-life supports twice-daily dosing, but BTK occupancy remains >90% over 12 hours due to irreversible binding.
Zanubrutinib is primarily metabolized by cytochrome P450 3A4 (CYP3A4). Following oral administration, it undergoes oxidation and further phase II metabolism. The major circulating metabolite is a product of CYP3A4-mediated oxidation.
Primarily metabolized by CYP3A4, with minor contributions from CYP2C8 and glutathione conjugation.
Biliary/fecal (87% as unchanged drug), renal (8% as unchanged drug)
Primarily hepatic metabolism (CYP3A4); fecal excretion accounts for approximately 86% (including 69% as metabolites, 17% as unchanged drug). Renal excretion is minimal (<1% unchanged).
96% bound to plasma proteins (mainly albumin)
97% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
3.23 L/kg (central Vd), indicating extensive tissue distribution
Approximately 34 L (approx. 0.5 L/kg for a 70 kg adult), indicating moderate distribution into tissues.
Oral: 48% under fasting conditions; high-fat meal decreases AUC by 30%
Oral bioavailability: approximately 70–75% (absolute bioavailability not determined in humans; estimate based on mass balance and exposure data).
No dose adjustment required for Cr Cl ≥30 m L/min. For Cr Cl <30 m L/min, reduce dose to 80 mg twice daily.
No dose adjustment required for Cr Cl ≥30 m L/min. For Cr Cl <30 m L/min, reduce dose to 100 mg orally once daily.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose to 80 mg twice daily. Child-Pugh C: not recommended.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose to 100 mg orally once daily. Child-Pugh C: Avoid use.
Safety and efficacy not established; no approved dosing.
Not approved for patients <18 years; safety and efficacy not established.
No specific dose adjustment; monitor for increased toxicity due to age-related renal/hepatic decline.
No specific dose adjustment; monitor for toxicity, especially infections and bleeding.
None
No boxed warning is included in the FDA-approved prescribing information.
Hemorrhage: Serious and fatal hemorrhagic events may occur. Monitor for signs of bleeding. Consider benefit-risk in patients requiring antiplatelet or anticoagulant therapy.,Infections: Fatal and serious infections (including pneumonia, sepsis) have occurred. Monitor for signs of infection and manage promptly.,Cytopenias: Neutropenia, thrombocytopenia, and anemia may occur. Monitor blood counts regularly.,Cardiac arrhythmias: Atrial fibrillation and atrial flutter have been reported. Monitor for symptoms of arrhythmia and manage appropriately.,Second primary malignancies: Including non-melanoma skin cancer, have been reported. Advise patients to use sun protection.,Tumor lysis syndrome: Can occur. Assess risk and monitor patients appropriately.
Hemorrhage: Fatal bleeding events have occurred; monitor for bleeding and manage appropriately,Infections: Serious infections (including opportunistic infections) have occurred; consider prophylaxis,Cytopenias: Grade 3/4 neutropenia, thrombocytopenia, and anemia; monitor blood counts,Second primary malignancies: Including skin cancers; advise sun protection,Atrial fibrillation and flutter: Monitor for cardiac arrhythmias,Hepatotoxicity: Elevations of liver enzymes; monitor hepatic function
None
None
Avoid grapefruit products and Seville oranges. No significant food effect on absorption; may be taken with or without food.
Avoid grapefruit, grapefruit juice, and Seville oranges due to CYP3A4 inhibition increasing acalabrutinib exposure. No other significant food interactions.
Based on animal studies and mechanism of action (BTK inhibitor), BRUKINSA (zanubrutinib) can cause fetal harm when administered to a pregnant woman. There are no adequate and well-controlled studies in pregnant women. In animal reproduction studies, administration of zanubrutinib to pregnant rats and rabbits during organogenesis resulted in embryo-fetal toxicity including increased post-implantation loss, reduced fetal body weights, and increased incidence of skeletal variations at exposures less than or equal to human clinical exposure at the recommended dose of 320 mg daily. Therefore, avoid use during pregnancy unless the potential benefit to the mother outweighs the potential risk to the fetus. If used, advise pregnant women of the potential risk to the fetus.
Acalabrutinib is a BTK inhibitor. Animal studies show embryo-fetal toxicity including malformations and reduced fetal weight at maternal exposures below clinical doses. In humans, no adequate data; however, based on mechanism and animal findings, there is potential risk of teratogenicity, especially during first trimester. Use during pregnancy should be avoided unless maternal benefit outweighs fetal risk.
There are no data on the presence of zanubrutinib in human milk, effects on the breastfed child, or effects on milk production. Zanubrutinib and its metabolites are excreted in the milk of lactating rats with concentrations approximately 2 times higher than maternal plasma (M/P ratio approximately 2). Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment with BRUKINSA and for at least 2 weeks after the last dose.
No data on acalabrutinib in human milk. Based on molecular weight and pharmacokinetics, excretion into breast milk is likely. M/P ratio unknown. Because of potential serious adverse reactions in breastfed infants, advise not to breastfeed during treatment and for 2 weeks after last dose.
No specific dose adjustments are recommended for BRUKINSA during pregnancy due to lack of pharmacokinetic data in pregnant women. However, pregnancy-induced physiological changes (e.g., increased plasma volume, altered hepatic metabolism) may affect drug concentrations. Standard dosing (320 mg once daily or 160 mg twice daily) is used if treatment is deemed necessary, with close monitoring for efficacy and toxicity. There are no pregnancy-specific pharmacokinetic studies to guide dose modification.
No established dosing adjustments for pregnancy. Pharmacokinetic changes in pregnancy (increased volume of distribution, altered clearance) may affect exposure; however, no specific dose recommendations are available. If used, therapeutic drug monitoring is not established; close clinical monitoring for efficacy and toxicity is advised.
Monitor for atrial fibrillation/flutter and hemorrhage; baseline ECG recommended. Dose adjust for severe hepatic impairment (Child-Pugh C). Avoid strong or moderate CYP3A inhibitors/inducers; use with caution in patients requiring antiplatelet or anticoagulant therapy.
Monitor for bleeding, especially if on antiplatelet or anticoagulant therapy. Acalabrutinib is a selective BTK inhibitor with minimal off-target effects compared to ibrutinib, but still carries risks of atrial fibrillation, hypertension, and infections. Start with 100 mg twice daily until progression or unacceptable toxicity. Administer with a full glass of water; do not open capsules. Consider dose reduction for severe hepatic impairment (Child-Pugh C).
Take BRUKINSA with or without food, but avoid grapefruit and Seville oranges.,Swallow capsules whole; do not crush or chew.,Inform your doctor of any bleeding or bruising, irregular heartbeat, or signs of infection.,Do not use antacids, proton pump inhibitors, or histamine-2 blockers without consulting your doctor.,If you miss a dose, take it as soon as remembered unless it is less than 12 hours until the next dose; then skip the missed dose.
Take exactly as prescribed, twice daily about 12 hours apart.,Swallow capsules whole with water; do not crush or chew.,Avoid grapefruit, grapefruit juice, and Seville oranges during treatment.,Report any signs of bleeding (unusual bruising, black/tarry stools, blood in urine) or infection (fever, chills) immediately.,Use effective contraception during treatment and for at least 1 week after last dose.,Do not stop or change dose without consulting your doctor.,Wash hands frequently and avoid crowds to reduce infection risk.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BRUKINSA vs ACALABRUTINIB, answered by our medical review team.
BRUKINSA is a Antineoplastic BTK Inhibitor that works by Zanubrutinib is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK). It forms a covalent bond with the cysteine residue at position 481 in the BTK active site, leading to sustained inhibition of BTK activity. This blocks B-cell receptor (BCR) signaling, thereby inhibiting the proliferation, migration, and survival of malignant B cells.. ACALABRUTINIB is a BTK Inhibitor that works by Acalabrutinib is a selective, irreversible inhibitor of Bruton tyrosine kinase. It forms a covalent bond with a cysteine residue in the active site, blocking B-cell receptor signaling and inhibiting malignant B-cell proliferation and survival.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BRUKINSA and ACALABRUTINIB depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BRUKINSA is: 320 mg orally once daily or 160 mg orally twice daily.. The standard adult dose of ACALABRUTINIB is: 100 mg orally every 12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BRUKINSA and ACALABRUTINIB in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BRUKINSA is classified as Category C. Based on animal studies and mechanism of action (BTK inhibitor), BRUKINSA (zanubrutinib) can cause fetal harm when administered to a pregnant woman. There are no adequate and well-. ACALABRUTINIB is classified as Category C. Acalabrutinib is a BTK inhibitor. Animal studies show embryo-fetal toxicity including malformations and reduced fetal weight at maternal exposures below clinical doses. In humans, . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.